Targowski Tomasz, Jahnz-Rózyk Karina, Przekora Piotr, Kucharczyk Aleksandra, Owczarek Witold
Wojskowy Instytut Medyczny w Warszawie, Centralny Szpital Kliniczny MON, Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii.
Pol Merkur Lekarski. 2011 Aug;31(182):106-10.
Morbidity on allergic diseases has been increasing in the last years. They are becoming important medical, social and economical problem all over the world. Allergic rhinitis and asthma are one of the most common allergic diseases. Specific allergen immunotherapy (SIT) has additional effects, not shared by pharmacological therapy; it has long-lasting preventive effect, especially the capacity to modify the natural course of the allergic diseases.
To evaluate the clinical efficacy and costs of specific immunotherapy in patients with allergic diseases.
The study were carried out on the group of 83 allergic patients treated with three-years subcutaneous SIT Clinical efficacy of SIT, costs of SIT and costs of one-year symptomatic treatment before and after SIT were assessed.
Three-years subcutaneous allergen-specific immunotherapy decreases allergic symptoms about 80% and reduces costs of symptoms-relieving drug about 70%. Patients with allergic bronchial asthma gain most clinical and economical benefits with SIT while presence of atopic dermatitis is correlated with less effective immunotherapy.
From public payer's and patient's perspective, SIT essentially reduces costs of symptoms-relieving treatment, especially in patients with allergic bronchial asthma. It can be a premise to consider to increase a level of refund of specific immunotherapy in Poland.
近年来，过敏性疾病的发病率一直在上升。它们正成为全球重要的医学、社会和经济问题。过敏性鼻炎和哮喘是最常见的过敏性疾病之一。特异性变应原免疫疗法（SIT）具有药物疗法所没有的额外效果；它具有持久的预防作用，尤其是改变过敏性疾病自然病程的能力。
评估特异性免疫疗法对过敏性疾病患者的临床疗效和成本。
对83例接受三年皮下SIT治疗的过敏性患者进行研究。评估SIT的临床疗效、SIT的成本以及SIT前后一年对症治疗的成本。
三年皮下变应原特异性免疫疗法可使过敏症状减轻约80%，并使缓解症状药物的成本降低约70%。过敏性支气管哮喘患者通过SIT获得的临床和经济效益最大，而特应性皮炎的存在与免疫疗法效果较差相关。
从公共支付者和患者的角度来看，SIT基本上降低了缓解症状治疗的成本，尤其是在过敏性支气管哮喘患者中。这可能是考虑提高波兰特异性免疫疗法报销水平的一个前提。
